_:nb65d6b0c883b484884cf23df60474bdexb0
<http://schema.org/description>
"The first ranibizumab biosimilar (Byooviz) has potential to alleviate financial burden associated with retinal conditions, but may not be the only new approval for ophthalmology treatment in 2022, explains Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health."
<https://www.centerforbiosimilars.com/view/cardinal-health-biosimilars-expert-discusses-dynamics-of-byooviz-launch>